207 related articles for article (PubMed ID: 37467318)
1. Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma.
Cichocki F; Zhang B; Wu CY; Chiu E; Day A; O'Connor RS; Yackoubov D; Simantov R; McKenna DH; Cao Q; Defor TE; Janakiram M; Wangen R; Cayci Z; Snyder N; Kumar A; Grzywacz B; Hwang J; Geffen Y; Miller JS; Maakaron J; Bachanova V
Sci Transl Med; 2023 Jul; 15(705):eade3341. PubMed ID: 37467318
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma.
Yoon DH; Koh Y; Jung M; Kwak JE; Shin EC; Hwang YK; Kim WS
Transplant Cell Ther; 2023 Apr; 29(4):253.e1-253.e9. PubMed ID: 36610490
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.
Bachanova V; Sarhan D; DeFor TE; Cooley S; Panoskaltsis-Mortari A; Blazar BR; Curtsinger JM; Burns L; Weisdorf DJ; Miller JS
Cancer Immunol Immunother; 2018 Mar; 67(3):483-494. PubMed ID: 29218366
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic natural killer cells for refractory lymphoma.
Bachanova V; Burns LJ; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lindgren BR; Cooley S; Weisdorf D; Miller JS
Cancer Immunol Immunother; 2010 Nov; 59(11):1739-44. PubMed ID: 20680271
[TBL] [Abstract][Full Text] [Related]
7. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL).
Chu Y; Lamb M; Cairo MS; Lee DA
Curr Treat Options Oncol; 2022 Mar; 23(3):381-403. PubMed ID: 35258793
[TBL] [Abstract][Full Text] [Related]
8. Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
Edri A; Ben-Haim N; Hailu A; Brycman N; Berhani-Zipori O; Rifman J; Cohen S; Yackoubov D; Rosenberg M; Simantov R; Teru H; Kurata K; Anderson KC; Hendel A; Pato A; Geffen Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139060
[TBL] [Abstract][Full Text] [Related]
9. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
10. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.
Gluck WL; Hurst D; Yuen A; Levine AM; Dayton MA; Gockerman JP; Lucas J; Denis-Mize K; Tong B; Navis D; Difrancesco A; Milan S; Wilson SE; Wolin M
Clin Cancer Res; 2004 Apr; 10(7):2253-64. PubMed ID: 15073100
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
Satwani P; Bavishi S; Saha A; Zhao F; Ayello J; van de Ven C; Chu Y; Cairo MS
Cytotherapy; 2014 Oct; 16(10):1431-40. PubMed ID: 24856896
[TBL] [Abstract][Full Text] [Related]
12. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E; Marin D; Banerjee P; Macapinlac HA; Thompson P; Basar R; Nassif Kerbauy L; Overman B; Thall P; Kaplan M; Nandivada V; Kaur I; Nunez Cortes A; Cao K; Daher M; Hosing C; Cohen EN; Kebriaei P; Mehta R; Neelapu S; Nieto Y; Wang M; Wierda W; Keating M; Champlin R; Shpall EJ; Rezvani K
N Engl J Med; 2020 Feb; 382(6):545-553. PubMed ID: 32023374
[TBL] [Abstract][Full Text] [Related]
13. CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma.
Cho MM; Song L; Quamine AE; Szewc F; Shi L; Erbe AK; Ebben JD; Turicek DP; Kline JM; Lafeber EO; Phillips MF; Ceas AS; Capitini CM
bioRxiv; 2024 Jan; ():. PubMed ID: 37333207
[TBL] [Abstract][Full Text] [Related]
14. Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells.
Deng X; Terunuma H; Nieda M; Xiao W; Nicol A
Int Immunopharmacol; 2012 Dec; 14(4):593-605. PubMed ID: 23063974
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4
Levy E; Reger R; Segerberg F; Lambert M; Leijonhufvud C; Baumer Y; Carlsten M; Childs R
Front Immunol; 2019; 10():1262. PubMed ID: 31231387
[TBL] [Abstract][Full Text] [Related]
16. Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma.
Nieto Y; Banerjee P; Kaur I; Kim KH; Fang D; Thall PF; Griffin L; Barnett M; Basar R; Hosing C; Ramdial J; Srour S; Daher M; Marin D; Jiang X; Chen K; Champlin R; Shpall EJ; Rezvani K
Transplant Cell Ther; 2024 Feb; 30(2):203.e1-203.e9. PubMed ID: 38042257
[TBL] [Abstract][Full Text] [Related]
17. Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation.
Mishra HK; Dixon KJ; Pore N; Felices M; Miller JS; Walcheck B
Front Immunol; 2021; 12():711621. PubMed ID: 34367174
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM
Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994
[TBL] [Abstract][Full Text] [Related]
19. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
20. Glycodelin-A stimulates the conversion of human peripheral blood CD16-CD56bright NK cell to a decidual NK cell-like phenotype.
Lee CL; Vijayan M; Wang X; Lam KKW; Koistinen H; Seppala M; Li RHW; Ng EHY; Yeung WSB; Chiu PCN
Hum Reprod; 2019 Apr; 34(4):689-701. PubMed ID: 30597092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]